Jonathan A. Hensel

Elisabeth-Krankenhaus Essen — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index771citations64works1.52yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone Metabolism and Diseases(12), Bone health and treatments(10), CAR-T cell therapy research(10), Bladder and Urothelial Cancer Treatments(9), Immunotherapy and Immune Responses(9)

Publications64 total

Proximal kissing stent extensions after stent therapy of the proximal external and internal iliac artery at the iliac bifurcation for recurrent claudication and erectile dysfunction

Radiology Case Reports·2025Open Access

Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumors

3 cited

Cytotherapy·2024· 3 citedOpen Access

SARS-CoV-2 antibody response duration and neutralization following natural infection

2 cited

Journal of Clinical Virology Plus·2023· 2 citedOpen Access

Supplemental figure legends from Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors

2023Open Access

Supplementary Figures from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity

2023Open Access

Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity

2023Open Access

Data from Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors

2023Open Access

Supplemental Figure 2 from Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors

2023Open Access

Data from Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors

2023Open Access

Supplemental Figure 1 from Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors

2023Open Access

Supplementary Figure from Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival

2023Open Access

Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity

2023Open Access

Data from Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival

2023Open Access

Supplemental figure legends from Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors

2023Open Access

Supplementary Methods from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity

2023Open Access

Data from Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival

2023Open Access

Supplementary Figure from Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival

2023Open Access

Supplemental Figure 1 from Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors

2023Open Access

Supplemental Figure 2 from Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors

2023Open Access

Supplementary Methods from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity

2023Open Access

page 1 of 4Next →

Frequent Co-authors

Selvarangan Ponnazhagan(25), Vinayak Khattar(12), Reading Ashton(12), Anandi Sawant(11), Jessy S. Deshane(10), Diptiman Chanda(9), Dan Theodorescu(9), Shari Pilon‐Thomas(9), Gene P. Siegal(8), Jason E. Duex(8), Garrett M. Dancik(8), Henry F. Frierson(8), Joo Hyoung Lee(7), Tatyana Isayeva(6), John E. Mullinax(6), Charles Owens(6), Michael G. Edwards(6), Matthew Beatty(5), Hong Wang(5), Girish Ramaswamy(4)